GlassScriptPhysician profile
Narasimha P Rao
NPI 1992789861
$6,175.46
in general payments reported to CMS, 2019-2025
30 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $1,349 · 2021: $2,009 · 2022: $1,227 · 2023: $417 · 2024: $81.94 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,134.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $817.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.18 | 2019-2022 | |
| Amgen INC. | $390.90 | 2019-2022 | |
| Boston Scientific Corporation | $362.88 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, General - Crm_crm |
| Astrazeneca Pharmaceuticals LP | $325.27 | 2019-2025 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $308.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $285.50 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $285.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $280.70 | 2019-2021 | |
| Pfizer INC. | $231.46 | 2019-2025 | |
| Esperion Therapeutics, INC. | $231.18 | 2020-2022 | |
| Medtronic, INC. | $201.53 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $147.07 | 2019-2021 | |
| Medtronic Vascular, INC. | $110.58 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $93.53 | 2023 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.52 | 2020-2022 | |
| Abbott Laboratories | $83.87 | 2019-2022 | |
| Novo Nordisk INC | $82.20 | 2021-2022 | |
| Zoll Circulation INC | $52.17 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.89 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $22.55 | 2021 | |
| Cordis US Corp. | $21.85 | 2025 | Mynx Control Venous |
| Aegerion Pharmaceuticals, INC. | $21.16 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.13 | 2021 | |
| Atricure, INC. | $18.34 | 2025 | Atriclip Laa Exclusion System |
| Bardy Diagnostics, INC. | $15.75 | 2020 | |
| Chiesi USA, INC. | $15.37 | 2023 | Cleviprex, Kengreal |
| Allergan, INC. | $11.43 | 2019 | |
| Itamar Medical INC | $8.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narasimha Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.